Articles

VISIBLE results from vedolizumab

Takeda's biologic successfully meets primary endpoint in VISIBLE 2 trial, inducing clinical remission in Crohn's disease patients
Written byKelsey Kaustinen
| 2 min read

OSAKA, Japan—Takeda Pharmaceutical Co. Ltd. had positive clinical data to share this week from its VISIBLE 2 trial of an investigational subcutaneous (SC) formulation of its gut-selective biologic vedolizumab. The trial explored vedolizumab as a maintenance therapy in adults with moderately to severely active Crohn's disease who achieved clinical response—which was defined as a ≥70 point decrease in Crohn's Disease Activity Index (CDAI) score from baseline (week 0)—at week six after two doses of open-label vedolizumab intravenous therapy at weeks 0 and 2. A statistically significant number of patients who received vedolizumab subcutaneously achieved clinical remission at week 52 compared to placebo, with clinical remission defined as a Crohn's Disease Activity Index (CDAI) score ≤150.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.